News Report · Endocrinology

WHO Issues New Guidelines on GLP-1 Therapies for Obesity Management

June 09, 2026

Clinical Perspective

The WHO's new guidelines on GLP-1 therapies for obesity management represent a significant shift in recognizing obesity as a chronic disease requiring comprehensive treatment strategies. By incorporating pharmacotherapy into a multimodal approach, healthcare providers can better address the complexities of obesity and improve patient outcomes.

Dr. Amit Desai · Endocrinology

The World Health Organization (WHO) has released its first guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for treating obesity, recognizing it as a chronic disease requiring comprehensive management. The guideline supports the use of GLP-1 therapies, including tirzepatide and semaglutide, as part of a multimodal approach to obesity care ^[6].

Clinical Context

Obesity is a complex, chronic disease affecting over one billion people globally, contributing to increased risks of cardiovascular disease, type 2 diabetes, and certain cancers. Current treatments often include lifestyle modifications and pharmacotherapy; however, many patients struggle to achieve and maintain significant weight loss. The recent updates in treatment guidelines aim to address the identified gaps in obesity management, emphasizing the role of GLP-1 receptor agonists as effective pharmacotherapy options. The WHO's new guidelines provide a framework for integrating these therapies into clinical practice, ensuring that patients receive comprehensive care tailored to their individual needs ^[6]^[7].

Key Findings

The WHO guideline on GLP-1 therapies emphasizes their role in obesity management as part of a comprehensive treatment strategy ^[6].
GLP-1 therapies, including tirzepatide and semaglutide, are now recommended for adults with obesity (BMI ≥30) as part of a multimodal approach that includes dietary changes and physical activity ^[7].
The guidelines highlight the importance of risk stratification to identify populations most likely to benefit from GLP-1 therapies, aiming to maximize treatment effectiveness and reduce obesity-related morbidity and mortality ^[6].
WHO's recommendations are conditional, reflecting the need for further research and data on long-term outcomes associated with GLP-1 therapy use in diverse populations ^[6].
The guideline aligns with the recent addition of GLP-1 therapies to the WHO Essential Medicines List, underscoring their significance in managing obesity and associated comorbidities ^[6].

Safety & Tolerability

Nausea reported with tirzepatide and semaglutide — monitor during treatment ^[1].
Vomiting reported — exact frequency not available in public source summary ^[1].
Diarrhea reported ^[1].
Risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide — advise patients to seek immediate medical attention if vision loss occurs ^[2].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception ^[1].
Complete adverse event profile available in the full prescribing information for tirzepatide and semaglutide ^[1].

What This Means for Clinical Practice

Clinicians treating obesity should consider GLP-1 therapies, such as tirzepatide and semaglutide, as first-line options for patients with a BMI of 30 or greater. The new WHO guidelines indicate that these therapies can significantly aid in weight management, emphasizing a holistic approach that includes lifestyle interventions. How can healthcare providers ensure equitable access to these therapies for all patients?

Study Design

The WHO guideline development process involved a comprehensive review of existing evidence on GLP-1 therapies, focusing on their efficacy and safety in treating obesity. The guideline was informed by expert consensus and aims to provide practical recommendations for healthcare providers in various settings. Key limitations include the need for ongoing research to establish long-term outcomes and effectiveness across diverse populations. The guideline does not address the use of GLP-1 therapies in pregnant women, as data in this population is lacking ^[6]^[7].

FAQ

What is tirzepatide approved for?

Tirzepatide is approved for the treatment of obesity in adults with a body mass index (BMI) of 30 or greater, as part of a comprehensive weight management program. The approval is based on evidence supporting its efficacy in weight loss and metabolic health improvement.

How does tirzepatide work?

Tirzepatide is a GLP-1 receptor agonist that mimics the action of the GLP-1 hormone, which helps regulate blood sugar levels and appetite. It enhances insulin secretion, reduces glucagon levels, and slows gastric emptying, leading to decreased food intake and weight loss.

What is the recommended dose of tirzepatide?

Full dosing guidance is available in the prescribing information for tirzepatide. Typically, it is initiated at a lower dose and titrated based on patient response and tolerability.

What are the most common side effects of tirzepatide?

Common side effects of tirzepatide include nausea, vomiting, and diarrhea. These are generally mild to moderate and tend to decrease over time as the body adjusts to the medication.

How does tirzepatide compare to semaglutide?

Both tirzepatide and semaglutide are GLP-1 receptor agonists effective in weight management. However, they have different dosing regimens and may have varying efficacy profiles in specific populations.

Who qualifies for tirzepatide treatment?

Tirzepatide is indicated for adults with obesity (BMI ≥30) who are seeking weight management as part of a comprehensive treatment plan that includes lifestyle changes.

WHO Issues New Guidelines on GLP-1 Therapies for Obesity Management

WHO Issues New Guidelines on GLP-1 Therapies for Obesity Management

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

FAQ

References

Get weekly drug updates for Endocrinology in your inbox.

Related Drug Updates

FDA Approves Tzield for Type 1 Diabetes: Delays Onset in Pediatric Patients

FDA Approves Semaglutide for Cardiovascular Risk: 20% MACE Reduction in SELECT Trial

FDA Approves Tirzepatide for Chronic Weight Management: 18% Weight Reduction in SURMOUNT-1 Trial

Verified HCP Portal